Drug Profile
Verdinexor - Antengene Therapeutics/Karyopharm Therapeutics
Alternative Names: ATG-527; KPT-335Latest Information Update: 29 Jul 2022
Price :
$50
*
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Karyopharm Therapeutics
- Class Antineoplastics; Antivirals; Hydrazines; Pyridines; Small molecules; Triazoles
- Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Post-transplant lymphoproliferative disorder; Systemic lupus erythematosus; Viral infections
- Preclinical Osteosarcoma
Most Recent Events
- 14 Jun 2022 Verdinexor is still in phase-I development in Viral-infections (In volunteers) in Australia (PO) (Antengene Corporation pipeline, June 2022)
- 14 Jun 2022 Antengene Corporation plans a phase I/II trial for Chronic active Epstein-Barr virus infection (CAEBV) and Systemic lupus erythematosus (Antengene Corporation pipeline, June 2022)
- 08 Apr 2022 Preclinical trials in Osteosarcoma in USA (unspecified route)